EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
Shuli Liu, Yang Wang, Yong Han, Weiya Xia, Ling Zhang, Shengming Xu, Houyu Ju, Xiangkai Zhang, Guoxin Ren, Liu Liu, Weimin Ye, Zhiyuan Zhang, Jingzhou Hu
Abstract
These results identify the EREG-EGFR-C-Myc pathway as a crucial axis that drives HNSCC oncogenesis and show that EREG expression could be a predictive functional marker of sensitivity to erlotinib therapy in HNSCC.
Topics & Concepts
ErlotinibCarcinogenesisHead and neck squamous-cell carcinomaCancer researchEpidermal growth factor receptorOncogeneGene knockdownBiologyCancerCell cultureHead and neck cancerCell cycleGeneticsLung Cancer Treatments and MutationsProtein Degradation and InhibitorsUbiquitin and proteasome pathways